SSBs Production Facility Design for WuXi AppTec Receives Honorable Mention at the ISPE Facility of the Year Awards 2014
![](/46/pdcnewsitem/03/37/83/yxgwl94ER885MfC.jpg)
The WuXi AppTec bulk cell culture production facility designed by Sartorius Stedim Biotech (SSB) received an honorable mention in the 2014 Facility of the Year Awards. The awards were presented by the International Society for Pharmaceutical Engineering (ISPE) at its Annual Meeting in Las Vegas last week.
WuXi AppTec faced the challenge of designing and building a highly flexible, cost-effective, multi-product facility for biologics production in line with cGMP standards for the US, EU and China within a short timeline. The company involved SSB’s bioprocess design consultant team early on in its planning stage. The SSB team performed risk assessments evaluating the relative impact of traditional versus single-use technologies. SSB estimated that WuXi could considerably reduce its timeline by selecting a fully single-use process train thus decoupling the process design from the facility build. The team carried out process modeling to evaluate equipment sizing and identified opportunities for downsizing utilities and for meeting higher classification room requirements by working with single-use technology.
Benefiting from SSB’s expertise in the design and implementation of fully single-use process trains, WuXi was able to achieve its goal in 18 months from conceptual design to commissioning and startup, and became the first biologics production facility in China to be compliant with cGMP standards for the US, EU, and China.
“SSB’s performance surpassed our expectations,” said Dr Ge Li, Chairman and CEO of WuXi AppTec. “We were delighted with the efficiency of SSB’s project management and with their expertise in single-use process implementation. We now have a highly flexible facility with scalable, disposable equipment from 50 L to 2,000 L, designed to meet the rapidly changing requirements of our clients. We are proud to be the manufacturer of the first biologics produced in China for clinical trials in the US.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance